Systemic Use of Bevacizumab for Recurrent Respiratory Papillomatosis: Who, What, Where, When, and Why?

• Authors: Craig S Derkay, Children's Hospital of the King's Daughters; Emily E Wikner, Eastern Virginia Medical School; Seth Pransky, Pediat Specialty Partners San Diego; Simon R Best, Johns Hopkins University; Karen Zur, Childrens Hospital of Philadelphia; Douglas R Sidell, Stanford University; Adam Klein, Emory University; Clark Rosen, University of California San Francisco; Frederick G Dikkers, University of Amsterdam; Romaine Johnson, University of Texas‐Southwestern, Dallas Texas
• Journal Title: LARYNGOSCOPE
• Volume: Volume 133, Number 1
• Publisher: WILEY | 2022-05-11, Pages 2-3
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.1002/lary.30180
• Subjects: Health Sciences, Medicine and Surgery
• Keywords: Science & Technology; Life Sciences & Biomedicine; Medicine, Research & Experimental; Otorhinolaryngology; Research & Experimental Medicine

Abstract

Recurrent respiratory papillomatosis (RRP) is a potentially lethal disease caused by the human papillomavirus (HPV) and characterized by recurrent papillomas in the aerodigestive tract. Cases of RRP are expected to be significantly reduced with increased acceptance of the HPV‐9 vaccine. Currently, the mainstay of RRP treatment is via surgical intervention, with a minority of patients requiring adjuvant medical therapies during their disease.